GlobalData on MSN4d
Metsera raises $215m in Series B round for weight loss candidates
Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.
Yahoo Finance5d
Metsera raises $215M to accelerate obesity drug plans
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Metsera, already a well-funded ...
FierceBiotech5d
High-flying Metsera follows phase 1 weight loss data with $215M series B raise
Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 ...
The Pharma Letter4d
Metsera bulks up cash pile for shot at obesity
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series ...
BioSpace5d
Fledgling Obesity Biotech Metsera Raises Another $215M for Long-Acting GLP-1
Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...
Business Wire5d
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio
NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced the close of ...
Crain's New York2d
Lower Manhattan weight loss startup competes with Big Pharma
Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...
pharmaphorum4d
Metsera gets $215m for obesity trials, and other financings
The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...
MM&M3d
Rx Rundown: Roche, Metsera, Intercept Pharmaceuticals and more
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...